Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1978 4
1979 13
1980 23
1981 69
1982 136
1983 70
1984 90
1985 151
1986 267
1987 474
1988 666
1989 788
1990 821
1991 778
1992 750
1993 722
1994 656
1995 614
1996 586
1997 464
1998 441
1999 407
2000 391
2001 356
2002 353
2003 308
2004 255
2005 260
2006 218
2007 223
2008 221
2009 216
2010 187
2011 207
2012 205
2013 161
2014 172
2015 126
2016 143
2017 112
2018 91
2019 29
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

12,944 results
Results by year
Filters applied: . Clear all
Page 1
Interleukin-2 and regulatory T cells in graft-versus-host disease.
Koreth J, et al. N Engl J Med 2011 - Clinical Trial. PMID 22129252 Free PMC article.
Interleukin-2 is critical for Treg cell growth, survival, and activity. We hypothesized that low-dose interleukin-2 could preferentially enhance Treg cells in vivo and suppress clinical manifestations of chronic GVHD. ...After a 4-week hiatus, patients with a response could receive interleukin-2 for an extended period. RESULTS: A total of 29 patients were enrolled. ...
Interleukin-2 is critical for Treg cell growth, survival, and activity. We hypothesized that low-dose interleukin-2
Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.
Rosenberg SA, et al. N Engl J Med 1988. PMID 3264384
Objective regression of the cancer was observed in 9 of 15 patients (60 percent) who had not previously been treated with interleukin-2 and in 2 of 5 patients (40 percent) in whom previous therapy with interleukin-2 had failed. ...Toxic effects of interleukin-2 occurred, although the treatment course was short (five days); these side effects were reversible. ...
Objective regression of the cancer was observed in 9 of 15 patients (60 percent) who had not previously been treated with interleukin
Low-dose interleukin-2 as a modulator of Treg homeostasis after HSCT: current understanding and future perspectives.
Matsuoka KI. Int J Hematol 2018 - Review. PMID 29234980
Based on the theory of low-dose IL-2 in which Treg can be selectively stimulated through the high-affinity IL-2 receptor, clinical studies have been conducted and demonstrated that low-dose IL-2 administration can restore Treg homeostasis and promote the expansion of this subset on the polymorphic processes of Treg reconstitution after HSCT. ...To further extend the indication of low-dose IL-2 to more patients with various immunological problems, the optimization of the timing and dosing of IL-2 intervention and the concomitant immune suppressive therapy according to each patient-based assessment are to be desired in the near future. ...
Based on the theory of low-dose IL-2 in which Treg can be selectively stimulated through the high-affinity IL-2 receptor, clin …
Interleukin-2 and leukemia.
Goodman M, et al. Leukemia 1998 - Review. PMID 9823939 Free article.
However, there remains a lack of correlation between the biologic and clinical effects of interleukin-2. The clinical activity of interleukin-2 appears to be greatest in myeloid leukemias. ...Large randomized studies are necessary to explore the role of interleukin-2 in leukemia....
However, there remains a lack of correlation between the biologic and clinical effects of interleukin-2. The clinical activity …
Interleukin 2.
Hamblin TJ. BMJ 1990 - Review. PMID 2106954 Free PMC article.
Interleukin-2 toxicity.
Siegel JP and Puri RK. J Clin Oncol 1991 - Review. PMID 2066765
Because of the ability of interleukin-2 (IL-2) to support the proliferation and activation of numerous types of immunocompetent cells and to support the survival of adoptively transferred lymphocytes, there has been considerable interest in its use in the immunotherapy of malignancies. ...Several adverse effects of IL-2 appear to be mediated by other cytokines whose production is induced by IL-2. Studies into the pathogenesis and manifestations of IL-2 toxicity have offered the hope of developing less toxic approaches to IL-2 therapy. ...
Because of the ability of interleukin-2 (IL-2) to support the proliferation and activation of numerous types of immunoc …
Recombinant interleukin-2.
Bruton JK and Koeller JM. Pharmacotherapy 1994 - Review. PMID 7885967
Recombinant interleukin (IL)-2 is a newly approved immunoregulatory protein produced by lymphocytes that exhibits a wide range of immunologic effects. ...Administration of low-dose IL-2 has emerged as a means of substantially reducing toxicity. At least in renal cell carcinoma, it appears that the response rate to low-dose IL-2 is comparable to that with higher dosages....
Recombinant interleukin (IL)-2 is a newly approved immunoregulatory protein produced by lymphocytes that exhibits a wide range …
Thoracic injection of low-dose interleukin-2 as an adjuvant therapy improves the control of the malignant pleural effusions: a systematic review and meta-analysis base on Chinese patients.
Han L, et al. BMC Cancer 2018. PMID 29980186 Free PMC article.
BACKGROUND: Interleukin-2 (IL-2) is an important immunotherapy cytokine for various diseases including cancer. Some studies reported the efficacy and safety on cisplatin combined with IL-2 versus cisplatin alone for treating malignant pleural effusion (MPE) through thoracic injection. ...In addition, compared with cisplatin alone, the presence of IL-2 improved the quality of life (QOL) of patients with MPE (p < 0.001). ...
BACKGROUND: Interleukin-2 (IL-2) is an important immunotherapy cytokine for various diseases including cancer. Some stu …
High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute.
Davar D, et al. J Immunother Cancer 2017. PMID 28923120 Free PMC article.
BACKGROUND: Durable remissions are observed in a fraction of metastatic melanoma patients treated with high-dose interleukin-2 (HD IL-2). ...HD IL-2 required ICU transfers in 11 patients and 1 death was attributed to HD IL-2. Pre-treatment lactate dehydrogenase (LDH) levels correlated significantly with progression-free survival [1-2× upper limit normal (ULN) HR 1.95; >2× ULN HR 2.32] and overall survival (1-2× ULN HR 1.67; >2× ULN 2.49). ...
BACKGROUND: Durable remissions are observed in a fraction of metastatic melanoma patients treated with high-dose interleukin-2
Managing toxicities of high-dose interleukin-2.
Schwartz RN, et al. Oncology (Williston Park) 2002 - Review. PMID 12469935 Free article.
Although high-dose interleukin-2 (IL-2, Proleukin), a highly toxic agent used in the treatment of renal cell carcinoma and melanoma, was initially associated with treatment-related mortality, it can, in the appropriate setting, be administered safely. ...This article reviews high-dose IL-2 toxicities and symptom management strategies and provides practical guidelines to facilitate the safe and effective administration of high-dose IL-2....
Although high-dose interleukin-2 (IL-2, Proleukin), a highly toxic agent used in the treatment of renal cell carcinoma …
12,944 results
Jump to page
Feedback